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Abstract: The tumor suppressor genes (TSGs) ING3 and ING5, members of the inhibitor of growth gene family, are effective in inhibition
of cell growth and induction of apoptosis. However, in many cancer types, one of the alleles of a TSG is lost through carcinogenesis,
while the remaining allele is usually inactivated through a process called loss of heterozygosity (LOH). Previous studies in head and
neck cancer revealed that allelic loss and reduced expression is a common pattern of ING gene family members. Fifty paraffin-embedded
breast cancer tissues were analyzed by polymerase chain reaction and denatured-polyacrylamide gel electrophoresis for LOH status.
The allelic deletion frequency of ING3 and ING5 were detected as 14% and 17% in breast cancer patients, respectively. No significant
relationship was detected between ING3 LOH status and clinicopathological variables. Our data also suggest that both ING3 and ING5
LOH statuses have no significant effect in overall survival and disease-free survival of breast cancer patients. These results provide a
rational explanation and relative contribution for the complexity of tumor formation, whereby allelic loss of ING3 and ING5 genes is not
a major factor for breast cancer but is rather a part of a larger complex mechanism.
Key words: Clinicopathological factors, early diagnosis, survival analysis, tumor suppressor genes

1. Introduction
Breast cancer is the most deadly form of cancer after lung
cancer, and after skin cancers it is the most common cancer
among women in the world. About 1 in 8 (12%) women in
the United States will have breast cancer in their lifetime.
According to the American Cancer Society, 232,340 new
women had an invasive breast cancer diagnosis and about
40,000 women died from breast cancer in the United States
in 2013. It is the cause of death for 1 out of every 36 women
(about 3%) (American Cancer Society, 2013).
Breast cancer mortality has been decreasing since
1989, and this decline has been seen especially in women
younger than 50. It is known that earlier detection through
screening and increased awareness about the disease
has led to these declines, as well as enhanced treatment
(Andersson and Janzon, 1997). Early diagnosis of breast
cancer before symptoms emerge is the most effective form
of treatment. Thus, understanding the genetic background
of breast cancer is essential for early diagnosis and finding
new biomarkers.
Breast cancer is the end point of multiple genetic events
in the breast tissue. One of these events, inactivation of
* Correspondence: egunduz@turgutozal.edu.tr
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tumor suppressor genes (TSGs), is considered one of the
most important mechanisms in tumorigenesis. Hence,
localization and identification of TSGs are of great interest
for a better understanding of cancer and the development
of molecular diagnostics as well as new drugs. One of the
important steps for the identification of a TSG is loss of
heterozygosity (LOH) analysis. LOH is commonly seen
in cancer, where it denotes the lack of a functional TSG in
the lost region. On the other hand, the other allele serves
as a functional gene, so this loss does not cause illness.
However, a point mutation, nondisjunction during mitosis,
or deletion of a chromosome segment can inactivate the
remaining copy of the TSG, leaving no TSG to protect the
body, and then the individual goes on to develop cancer
(Knudson, 1971).
The first member of the inhibitor of growth (ING)
family was discovered by Riabowol’s group in 1996 by using
subtractive hybridization (Garkavtsev et al., 1996). Our
group identified its genomic structure in 2000 (Gündüz et
al., 2000). We showed that ING1 encodes a 33-kDa protein
(p33ING1b). In that study, ING1 was also shown to be a
tumor suppressor gene. The loss of ING1 gene expression
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has been shown in numerous cancer types and ING1
gene knockout mice have been found to be cancer-prone.
Subsequently, we and other groups identified 4 additional
human ING genes (ING2–ING5) (Gündüz et al., 2000;
Gündüz et al., 2002; Shiseki et al., 2003; Gong et al., 2005;
Soliman and Riabowol, 2007; Gündüz et al., 2008; Unoki
et al., 2008; Coles and Jones, 2009). Among these genes,
ING3, encoding a 46.8-kDa protein (p47ING3) with a
C-terminal plant homeodomain (PHD) finger motif,
was subsequently identified through a computational
domain search in 2003 (Gündüz et al., 2000). It has been
mapped on chromosome 7 at the locus 7q31 and encodes 2
variants (Figure 1). The other members of the ING family,
including ING5, were identified through a computational
sequence homology search in the same year (Shiseki et al.,
2003). ING5 has been mapped on chromosome 2 at locus
2q37.3 and encodes 1 variant (Figure 2).
ING genes are TSGs. They play roles in a wide
variety of cellular processes. They are involved in cell
cycle checkpoints and cell cycle progression as well as
induction of apoptosis. ING1 expression is significantly

decreased in 44% of human primary breast cancers and
100% of established breast cancer cell lines. Decreased
ING1 expression has been identified in many solid and
blood tumors (Gündüz et al., 2009). Additionally, ING2,
ING3, and ING4 gene expression is decreased in human
melanoma cancer (Aguissa-Toure et al., 2011).
The role of ING3 in regulation of the cell cycle and
apoptosis has been determined. Ectopic expression of
ING3 in RKO cells, a colon cancer cell line, resulted in
decreased colony formation, possibly by reducing the
number of cells in S phase (Nagashima et al., 2003; Shiseki
et al., 2003).
Although we have limited information about ING5
function, very recent transfection experiments have
demonstrated that ING5 reduces colony-forming efficiency,
inhibits S-phase progression, and induces apoptosis in a
p53-dependent manner. ING5 can also induce expression
of the cyclin-dependent kinase inhibitor p21 (Shiseki et al.,
2003), a p53-target gene. These results suggest that ING5
has a role in regulation of cell growth and p53 activity, but
further studies of ING5 function are needed.

Figure 1. ING3 gene is composed of 13 exons and has 2 transcripts. Domains are as indicated above.

Figure 2. ING5 gene is composed of 8 exons and has 1 transcript. Domains are as indicated above.
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To our knowledge, there has been no prior study
examining the LOH status of ING3 and ING5 in breast
cancer. In this study, we examine for the first time the LOH
status of ING3 and ING5 in breast cancer tissues. We also
investigate the relation between the genes’ LOH statuses
and breast cancer patient survival.
2. Materials and methods
2.1. Tissue samples
Formalin-fixed paraffin-embedded archival matched
tumor and macroscopically normal samples of 50 patients
(median age: 51.9 years; range: 27–78 years) diagnosed
with invasive ductal breast cancer between 2006 and 2011
were obtained from the Department of Pathology, Faculty
of Medicine, Turgut Özal University. All tissues were frozen
in liquid nitrogen immediately after surgery and stored at
–80 °C until the extraction of DNA and RNA. All tumors
were confirmed as invasive ductal breast carcinoma in the
Department of Pathology.
These samples were collected after acquisition of
informed consent from each patient and approval of the
study by the Institutional Human Ethics Committee of
Turgut Özal University.
Tumor histology was determined according to the
2003 criteria of the World Health Organization. Tumors
were graded according to the Bloom–Richardson grading
scale. Each tumor and normal breast tissue sample was
histopathologically confirmed for the presence or absence
of cancer cells. Tumor samples containing more than 70%
tumor cells were selected. ER, PR, and HER2 statuses were
determined by immunohistochemistry.
2.2. Extraction of genomic DNA
Tumor and normal tissues were deparaffinized and
rehydrated in a decreasing alcohol series prior to DNA
extraction by use of the Pure Link Genomic DNA Mini
Kit (Invitrogen, USA). The extracted genomic DNA was
finally eluted in 100 µL of Tris-HCl buffer (10 mM, pH
9.0).
2.3. Polymerase chain reaction and denaturedpolyacrylamide gel electrophoresis
Specific primers were designed for ING3 and ING5 gene
regions for allelic deletion. Polymerase chain reaction
(PCR) was carried out in 25 µL of total reaction volume
with 12.5 µL of master mixture (QIAGEN), 0.5 µL (20
pmol) of each primer, 2 µL of genomic DNA, and 9.5 µL of
dH2O. Initial denaturation at 94 °C for 5 min was followed
by 35 cycles of a denaturation step at 94 °C for 30 s, an
annealing step at 54 °C (ING3) or 60 °C (ING5) for 30 s,
and an extension step at 72 °C for 1 min. A final extension
step at 72 °C for 5 min was added. Amplicons were run
in agarose gel electrophoresis and an appropriate amount
of PCR amplicon for both normal and tumor samples
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was loaded into denatured-polyacrylamide gel. Next,
2–4 µL of the PCR mixture was mixed with 2X loading
dye (95% formamide, 20 mM EDTA, 0.05% bromphenol
blue, and 0.05% xylene cyanol, ddH2O), heat denatured,
chilled on ice, and then electrophoresed through an 8%
polyacrylamide gel containing 8 M urea. DNA fragments
were visualized by the silver staining method (Bassam and
Gresshoff, 2007).
LOH was determined if one of the heterozygous alleles
showed at least 50% reduced intensity in tumor DNA as
compared with the corresponding normal DNA (Figure
3). This decision was made by direct visualization in cases
with clear deletion as compared to normal allele.
2.4. Statistical analysis
The Mann–Whitney U test as a nonparametric method
and Pearson’s chi-square test were used to evaluate the
correlation between ING3 and ING5 genes and the
clinicopathological characteristics of the patients (Table).
Survival curves were calculated according to the Kaplan–
Meier method. For comparison of survival between LOHnegative and LOH-positive ING genes, the log-rank test
was used. Overall survival in months was calculated from
the day after surgery to the last follow-up examination or
death. The survival periods of the patients who were still
alive were noted along with the date of the most recent
follow-up appointment. The duration of disease-free
survival (DFS) was determined from the day after surgery
to the initial recurrence of the surgically resected cancer,
as evaluated by clinical examination. SPSS 15 for Windows
(SPSS, Chicago, IL, USA) was used for all statistical
manipulations and all results with a P-value of less than
0.05 were considered to be statistically significant.
3. Results
We included 50 breast cancer samples in the study. We were
unable to carry out PCR for the ING5 gene in some samples.
Our results showed that 14% of the patients presented LOH
of ING3, 58% of the patients were normal for ING3, and
28% of the patients’ results were not informative (Figures
4 and 5). Likewise, 17% of the patients presented LOH of
the ING5 gene, 62% of the patients had no deletion at the
ING5 gene locus, and 21% of the patients’ results were not
informative (Figures 4 and 5). Lymphovascular invasion
was identified in 35% of the patients. Nipple invasion was
identified in 70% of the patients, while ER was identified
in 60.5% of the patients and PR in 60.5% of the patients.
Fifty-eight percent of the patients were smokers and 2.3%
of patients consumed alcohol.
First, we investigated the relationship between
LOH status of ING3 and ING5 genes and most clinical
markers. No significant relationship was detected between
ING3 LOH status and tumor grade (P = 0.967), absence
or presence of lymph-node metastasis (P = 0.185),
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Figure 3. Primary LOH data from 6 representative breast cancer samples. N, Normal
DNA; T, tumor DNA. Case 5 shows LOH of ING5 and case 10s show LOH of ING3; case
6 and case 11 are not informative; case 4 and case 13 show retention of heterozygosity.
Table. Clinicopathological characteristics of patients.
Criteria

n

Age (mean)

52.6

%

Tumor status

Criteria

n

%

Criteria

n

%

Smoking

25

58

Alcohol usage

1

2.3

Node status

T1

9

21

N0

12

28

ING3 LOH-

21

58

T2

25

58

N1

13

30

ING3 LOH+

5

14

T3

5

11

N2

11

25.6

ING5 LOH-

30

62

T4

1

2.3

N3

5

11.6

ING5 LOH+

8

17

Lymphovascular invasion

15

35

ER

26

60.5

Chemotherapy

15

40

Nipple invasion

30

70

PR

26

60.5

Radiotherapy

14

32.6

lymphovascular invasion (P = 0.782), nipple invasion (P
= 0.199), age (P = 0.845), smoking (P = 1.000), alcohol
consumption (P = 0.739), and application of chemotherapy
(P = 0.201) or radiotherapy (P = 0.626).
Likewise, no significant relationship was detected
between LOH status of ING5 and tumor grade (P = 0.711),
absence or presence of lymph-node metastasis (P = 0.107),
lymphovascular invasion (P = 0.100), nipple invasion (P

= 0.213), age (P = 0.166), smoking (P = 1.000), alcohol
consumption (P = 0.564), and application of chemotherapy
(P = 0.112) or radiotherapy (P = 0.619).
3.1. ING3 and ING5 genes and survival analysis
Both overall survival (OS) and DFS were determined. All
patients were enrolled in a follow-up program. The followup time was between 22 and 90 months. Valid follow-up
data were available for 42 (84%) of 50 breast cancer patients.
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Figure 4. Percentage of ING3 and ING5 LOH samples with respect to normal and noninformative samples.

Figure 5. LOH analysis of ING3 and ING5 genes in breast cancer patients. Schematic representation of LOH distribution. Case
numbers are shown across the top. Genes are shown to the left.

Correlations between ING3 and ING5 LOH statuses and the
patients’ OS and DFS were analyzed using the univariate
Kaplan–Meier method. The mean overall survival in the
ING3 gene LOH-negative group was 54 months (range:
22–90 months) and that in the LOH-positive group was 40
months (range: 28–71 months) (P-value for log-rank test =
0.824). The log-rank test showed that patients in the ING3
LOH-positive group did not have significantly shorter OS
than those in the ING3 LOH-negative group (P = 0.824;
Figure 6a). The mean DFS in the ING3 gene LOH-negative
group was 49 (range: 22–90) months and that in the ING3
gene LOH-positive group was 40 (range: 21–51) months
(P-value for the log-rank test = 0.767; Figure 6b). The mean
OS in the ING5 gene LOH-negative group was 61 months
and that in the ING5 gene LOH-positive group was 51.5
months (P-value for log-rank test = 0.102; Figure 7a).The
mean DFS in the LOH-negative group was 54 months and
that in the LOH-positive group was 51.5 months (P-value
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for the log-rank test = 0.125; Figure 7b). These data suggest
that neither ING3 nor ING5 LOH status has significant
effect on OS and DFS of breast cancer patients.
4. Discussion
Although the exact functions of the ING genes have not
been fully clarified, the gene products mainly have roles
in transcriptional regulation, apoptosis, the cell cycle,
angiogenesis, and DNA repair through p53-dependent
and -independent pathways, and they form complexes
with histone acetyltransferases and histone deacetylases
(Campos et al., 2004).
Loss of heterozygosity in ING3 was found in
ameloblastoma, renal cell carcinoma, and head and neck
squamous cell carcinoma (HNSCC; Shridhar et al., 1997;
Borkosky et al., 2010). Decreased ING3 mRNA expression
was also found in HNSCC and melanoma (Wang and Li,
2006; Gündüz et al., 2008).
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Figure 6. Overall and disease-free survival in the groups of breast cancer patients with LOH-negative and LOH-positive ING3 gene.
Kaplan–Meier survival curves for the total number of cases (n = 26) were stratified by ING3 LOH states. The cases were divided into
LOH-negative and-LOH positive groups. (a) The mean overall survival in the LOH-negative group was 54 months and that in the LOHpositive group was 40 months (P-value for log-rank test = 0.824). (b) The mean disease-free survival in the LOH-negative group was 49
months and that in the LOH-positive group was 40 months (P-value for the log-rank test = 0.767).

Figure 7. Overall and disease-free survival in the groups of breast cancer patients with LOH-negative and LOH-positive ING5 gene.
Kaplan–Meier survival curves for the total number of cases (n = 37) were stratified by ING5 LOH states. The cases were divided into
LOH-negative and LOH-positive groups. (a) The mean overall survival in the LOH-negative group was 61 months and that in the LOHpositive group was 51.5 months (P-value for log-rank test = 0.102). (b) The mean disease-free survival in the LOH-negative group was
54 months and that in the LOH-positive group was 51.5 months (P-value for the log-rank test = 0.125).
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Our previous study on head and neck cancer showed
that about half of 71 tumor samples demonstrated
downregulation of ING3 compared to their matched
normal counterparts. Even if most clinicopathological
variables were not significantly related to ING3
downregulation or p53 mutation status, a significant
relationship was determined in terms of OS between the
cases with low and normal to high ING3 expression. At 5
years of follow-up, approximately 60% of the patients with
normal to high ING3 expression had survived, whereas
this rate was 35% in the patients with low ING3 expression.
Multivariate analysis also showed downregulation of ING3
as an independent prognostic factor for poor OS. These
results reveal that ING3 would function as a potential
tumor suppressor molecule and that low levels of ING3
may point to an aggressive nature of head and neck cancer
(Gündüz et al., 2008).
Loss of heterozygosity in ING5 was found in HNSCC
and oral cancer. Decreased ING5 mRNA expression was
also identified in ovarian cancer and HNSCC (Cengiz et
al., 2007, 2010). Our group determined that loss of the
ING5 chromosome locus was related to oral cancer. In our
study, a high rate of LOH in oral cancer was demonstrated.
Decreased expression of ING5 mRNA was also revealed
in 61% of oral squamous cell carcinomas as compared to
the matched normal samples. Because of tumor-specific
mutation and downregulation of ING5 mRNA, it was
suggested as a TSG in oral squamous cell carcinoma
(Cengiz et al., 2010).
A previous study suggested that a decline in nuclear
ING5 localization and cytoplasmic translocation are
involved in tumorigenesis and tumor differentiation in
HNSCC. Nuclear ING5 may regulate the transactivation
of target genes and may accelerate apoptosis and cell cycle
arrest by interacting with the p300 and p21 proteins. ING5
may function as a TSG or oncogene tightly linked with p53
status, and may have an important role in the prognosis of
HNSCC patients (Li et al., 2010).
Zhang et al. showed that overexpression of ING5 suppressed cell proliferation only in the presence of INCA1,
while ING5 had no effect in INCA1 ( - / - ) murine embryonic fibroblasts (MEFs). ING5 overexpression also triggered a delay in S-phase progression, which required the
inhibitor of cyclin A1 (INCA1). Furthermore, ING5 overexpression accelerated Fas-induced apoptosis in INCA1 (
+ / + ) MEFs, while Fas antibody did not induce apoptosis
in INCA1 ( - / - ) MEFs. Taken together, these results suggest that ING5 is a growth suppressor with reduced expression in AML whose functions depend on its interaction
with INCA1 (Zhang et al., 2011).
Another study showed that among 18 frozen samples
of colorectal carcinoma, significantly increased expression
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of ING5 protein was observed in carcinoma in comparison
with adjacent mucosa in 14 cases (77.8%; P < 0.05), and
71.4% (10/14) of carcinoma cases exhibited upregulation
of ING5 mRNA. Nuclear ING5 expression was negatively
correlated with tumor size, depth of invasion, degree of
dedifferentiation, and cancer staging (P < 0.05). In contrast,
cytoplasmic ING5 expression was positively correlated
with depth of invasion, lymphatic invasion, and cancer
staging (P < 0.05). It was suggested that aberrant ING5
expression may have a role in pathogenesis, growth, and
invasion of colorectal carcinomas and could be considered
as a remarkable marker to estimate aggressiveness of
colorectal carcinomas (Zheng et al., 2011).
Increased expression of ING5 mRNA was demonstrated
in gastric carcinoma in comparison with paired mucosa (P
< 0.05). Lower expression of nuclear ING5 was detected
in gastric dysplasia and carcinoma as compared to that in
nonneoplastic mucosa (P < 0.05). Gastric nonneoplastic
mucosa and metastatic carcinoma showed more expression
of cytoplasmic ING5 than did gastric carcinoma and
dysplasia (P < 0.05) (Xing et al., 2011).
Survival analysis showed that nuclear ING5 was
associated with favorable prognosis of gastric carcinoma
patients (P < 0.05). It was proposed that aberrant ING5
expression may play a role in pathogenesis, growth, and
invasion of gastric carcinomas and could be considered as
a striking marker to estimate aggressiveness and prognosis
of gastric carcinoma (Xing et al., 2011).
It has also been shown that ING5 can affect sensitivity
to some drugs. Mendes-Pereira et al. (2012) showed that
silencing ING5 causes sensitivity to tamoxifen.
This is the first study to analyze LOH status of ING3
and ING5 and examine its possible correlation with
clinicopathological factors. In the current study, we
analyzed the LOH status of the ING3 and ING5 genes;
afterwards, we compared it with the clinicopathological
characteristics of breast cancer patients. No significant
relationship was detected between LOH statuses of the
ING3 and ING5 genes and clinical markers including age,
smoking and alcohol consumption, absence or presence of
lymph-node metastasis, nipple invasion, and application
of chemotherapy or radiotherapy. We did not find a
relationship between LOH statuses of ING3 and ING5
genes and OS or DFS; other genetic and nongenetic factors
could be considered to contribute to the factors related to
OS and DFS, such as local recurrences, metastasis, and
aggressive phenotype.
In conclusion, our current study has confirmed that
patients with LOH in both ING3 and ING5 have shorter
OS and DFS, but this is not significant statistically. There
is also no significant relationship between the LOH
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status of ING3 and ING5 genes and any clinical features.
Comparative analysis of other genes, including various
ING family members, in subsequent studies would give us
more valuable and clinically applicable results.
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